Clinical Trial

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Name: SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer — clinical trial record (NCT07109284)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NeoSaciA

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.

Trial Details

NCT Number	NCT07109284
Lead Sponsor	West China Hospital
Conditions	ER+HER2- Breast Cancer
Enrollment	55 participants
Start Date	2025-09
Primary Completion	2028-01 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-07